Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of SCT1000 14-valent HPV vaccine in healthy women aged 18-45 years
CTR20232472Phase 3Active
- Sponsor
- Nuoning Biotechnology
- Start
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant 14-valent human papillomavirus vaccine in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma, vaginal cancer, anal cancer, sponsored by Nuoning Biotechnology. Started Aug 2023; status: active.
02
Drugs
recombinant 14-valent human papillomavirus vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal canceranal cancer
Beyond the preview
Go deeper on CTR20232472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232472.